NCT02273102View on ClinicalTrials.gov

Study of TCP-ATRA for Adult Patients With AML and MDS

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 2, 2015

Primary Completion Date

November 8, 2018

Study Completion Date

July 1, 2020

Conditions
Acute Myelogenous LeukemiaMyelodysplastic SyndromesLeukemia
Interventions
DRUG

Tranylcypromine

Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.

DRUG

Tretinoin

45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.

Trial Locations (1)

33136

University of Miami, Miami

All Listed Sponsors
collaborator

Women's Cancer Association

UNKNOWN

collaborator

Gabrielle's Angel Foundation

OTHER

lead

University of Miami

OTHER

NCT02273102 - Study of TCP-ATRA for Adult Patients With AML and MDS | Biotech Hunter | Biotech Hunter